Download - Alzheimer’s disease
![Page 1: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/1.jpg)
AD is a PROGRESSIVE IRREVERSIBLE neurodegenerative disease, for which there is no effective treatment yet
Epidemiology 1-AD is the most common form of dementia, accounting for >60% of all the cases.
2-Most of the cases of AD ARE SPORADIC. The prevalence of inherited forms of AD is <0.1%.
3-Risk factors for sporadic AD:-aging, head injuries, hormonal changes, vascular diseases, inflammation, ApoE e4 allele polymorphism, exposure to metals, like Cu++ and Zn++
Alzheimer’s disease
Numbers about AD
Increased life expectancy, more AD patients
Worldwide:2001: 24 million. Expected to double in 20 years
2040: 81 million
U.S.:2011: > 5 million AD patients, 10 million caregiversU.S. government spends ~ $200 billion/year
Projection for U.S. only 2040:11.5 million AD patients, 23 million caregivers; > 400 billion/year
![Page 2: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/2.jpg)
http://scienceblogs.com/neurophilosophy/Alzheimer
A nissl stain tissue section (left) and a Bielkhowsky’s stain section from Augustine Deter’s brain (right)
First description of tangle and plaque pathology by Alois Alzheimer (1901)
![Page 3: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/3.jpg)
Alzheimer’s disease
AD is a progressive neurodegenerative disorder affecting the elderly population. Once it starts, it progresses with aging.
It is characterized by the presence of lesions both at an extracellular level (the -amyloid plaques), and at an intracellular levels (the Neurofibrillary tangles, NFT).
The presence of the lesions correlates with both reduction in the volume of the brain (as a consequence of the neurodegenerative phenomena), and with cognitive decline associated to loss of memory.
AD is a form of Dementia.
![Page 4: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/4.jpg)
The loss of intellectual functions (such as thinking, remembering, and
reasoning) of sufficient severity to interfere with a person’s daily
functioning.
Dementia is not a disease itself but rather a group of symptoms that may
accompany certain diseases or conditions. Symptoms may also include
changes in personality, mood, and behavior.
Dementia is irreversible when caused by disease or injury but may be
reversible when caused by drugs, alcohol, hormone or vitamin imbalances,
or depression.
Definition of Dementia
![Page 5: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/5.jpg)
Increasing and persistent forgetfulness
Difficulty performing familiar tasks
Problems with finding the right words to express your thoughts
Disorientation with time and place
Poor or impaired judgment
Problems with abstract thinking
Putting everyday items in illogical places
Mood, behavior or personality changes.
Symptoms in AD
![Page 6: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/6.jpg)
Someone withAlzheimer's diseasesymptoms
Someone with normalage-related memorychanges
Forgets entire experiences Forgets part of an experienceRarely remembers later Often remembers later
Is gradually unable to followwritten/spoken directions
Is usually able to followwritten/spoken directions
Is gradually unable to usenotes as reminders
Is usually able to use notes asreminders
Is gradually unable to carefor self
Is usually able to care for self
Comparison between AD signs and age-related memory changes
![Page 7: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/7.jpg)
Normal
AD
MRI
www.elements4health.com
PET
Anatomy of the Alzheimer’s disease brain
![Page 8: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/8.jpg)
Alzheimer’s disease: characterized by extracellular depositions, the -amyloid plaque, and intracellular depositions, the Neurofibrillary Tangles (NFT) comprised of Paired Helical Filaments (PHF), aggregates of hyperphosphorylated protein tau.
Deposition of fibrillar proteinacious material in Alzheimer’s disease
![Page 9: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/9.jpg)
Origin of NFTs and the mechanism of tau pathology
1- Tau is a microtubule-associated protein that regulates cytoskeleton structure.
2- Tau is hyperphosphorylated in AD.
3- When highly phosphorylated, tau is sequestered into aggregates (PHF and NFT) and causes disruption of microtubules, that ultimately leads to cell death.
www.emdbiosciences.com
![Page 10: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/10.jpg)
The -Amyloid Plaque
A
proteolysisAPP
TMD
NH2 COOH
amyloidogenic processing pathway
Mechanisms of A pathology:
Plaque: unknownA: oligomers affect synaptic activity and neurotransmitter release
A oligomers
Origin of the -amyloid plaque
![Page 11: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/11.jpg)
The -amyloid plaque
1- -amyloid is DIFFERENT from amyloid. -amyloid contains specifically the -amyloid peptide, an approximately 4kDa peptide (A40, A42) deriving from the amyloid precursor protein APP when it undergoes the so called amyloidogenic pathway. -amyloid plaque contains also ubiquitin and other proteins coming from degenerative neurons and glial cells.
2- The -amyloid peptide is insoluble in water. When released from the precursor protein it assumes a -sheet conformation that makes it hydrophobic.
3- -amyloid peptides forms oligomers that may affect neurotransmitter release and synaptic plasticity. Oligomers will further aggregates in larger structures called fibrils, that will form the core of the -amyloid plaque, depositing in the extracellular matrix.
4- The size of the plaque will increase following the progression of the disease. Scientific clear evidences are still missing in order to understand whether the plaque is a consequence or a cause of AD. Indeed, A andplaques formation are associated to neuronal death. Inherited forms of AD lead to substantial increase of Aproduction.
![Page 12: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/12.jpg)
APP processing and formation of aggregates of beta-amyloid
![Page 13: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/13.jpg)
sAPP
A
secretase
secretase
C99
TMDAPP
secretase secretase
Amyloidogenic processing of APP
NH2 COOH
COOHNH2
![Page 14: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/14.jpg)
Structure of the -Amyloid peptide
25-35, the most critical region for the change of conformation from -sheet to -sheet
![Page 15: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/15.jpg)
Genetic of AD
-Depending on the kind of mutation and on the gene that carries it, the onset of the disease is SIGNIFICANTLY EARLIER than in sporadic cases (<before 65 years of age).
All the mutations are autosomal dominant, and involve
*APP protein
*Members of the -secretase complex, like Presenilin 1 (PS1) and Presenilin 2 (PS2)
![Page 16: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/16.jpg)
Mutations on APP
Swedish mutation: K670M/N671L, facilitates the amyloidogenic processing of APP by increasing the affinity for and the cleavage by -secretase of ~100 times.Dutch Mutation: E693Q, induces cerebral amyloidosis Arctic Mutation:E693G enhances -Amyloid protofibril formationLondon Mutation: V717I, Affects the cleavage of -secretase
K670M/N671L
Swedish MutationV717ILondon Mutation
E693GArctic Mutation
![Page 17: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/17.jpg)
sAPP
A
secretase
secretase
C99
TMDAPP
secretase!!! secretase!!!
Amyloidogenic processing of APP
NH2 COOH
COOHNH2
K670M/N671L V717I
E693G
![Page 18: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/18.jpg)
46 y DS(Lott and Dierssen, 2010) http://www.hcplive.com/articles/Alzheimers
-Promoter mutations that increase APP expression are associated with Alzheimer disease (Thenus et al., 2006).
Trisomy of Chromosome 21, Down SyndromeThe higher the levels of APP, the more the Aand AD pathology
A positive amyloid plaques
Human AD brain
![Page 19: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/19.jpg)
Mutations on Presenilins
PS1 (on chromosome 14) PS2 (on chromosome 1) are ~450 aa long aspartyl proteases comprised of 7- to 8- transmembrane spanning domains. They are the catalytic part of a tetrameric protein complex called -secretase, able to cleave APP at the end of the sequence for -Amyloid peptides, generating -Amyloid species.
More than 70 mutations on PS1 gene account for inherited AD.
Two mutations on PS2 gene account for inherited AD.
![Page 20: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/20.jpg)
Hardy and Selkoe, 2002
PS1 mutations and APP
![Page 21: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/21.jpg)
sAPP
A
secretase
secretase/mutantPS1
C99
TMDAPP
secretase secretase
Amyloidogenic processing of APP
NH2 COOH
COOHNH2
![Page 22: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/22.jpg)
The -Amyloid Plaque
Alois Alzheimer: “miliary bodies (the plaques) and dense bundles of fibrils (NFT)”
![Page 23: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/23.jpg)
Characteristic of the -amyloid plaque
-is extracellular
-normally, it has a core composed of the -amyloid peptide
-it can be cored (with an intensely stained core with a weak periphery stain-halo) or diffused, which do not have a core and the immunoreactivity is uniform over the plaque.
-aggregation is massive in the center, and diffused at the sides (disaggregation hypothesis?)
-diameter ranges between 20m and 90m
-is composed of dystrophic neurites, -amyloid peptides (40/42/43), ubiquitin, tau protein and other proteins, some involved in the generation of -amyloid, like the secretases.
![Page 24: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/24.jpg)
Amyloid: definition
Insoluble fibrous protein aggregations sharing specific structural traits:-Insolubility in water--sheet conformation-largest aggregates deposit extracellularly-positive to the staining with specific dyes, such as Congo Red -associated with tissue degeneration (cause or consequence?)
-Amyloid
Are formations of amyloid characterized by a core specifically formed by -amyloid peptides, a product of the so called amyloidgenic processing of a larger precursor, the protein APP (Amyloid Precursor Protein)
![Page 25: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/25.jpg)
Congo red staining of amyloid plaques
Under polarized light Under unpolarized light
![Page 26: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/26.jpg)
How to specifically detect -Amyloid plaques?
Using antibodies that specifically recognize the different -Amyloid peptides, A 1-40, A 1-42, A 1-
43
![Page 27: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/27.jpg)
-Amyloid peptides
40/42 43
![Page 28: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/28.jpg)
-Amyloid plaques depositions follow the progression of AD
![Page 29: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/29.jpg)
A40, A42 and A43 are part of the -amyloid plaque in AD
![Page 30: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/30.jpg)
Levels of deposited A40, A42 and A43 follow the progression of the disease
![Page 31: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/31.jpg)
Diagnosis of AD
At the moment, the exact diagnosis for AD can be performed only post-mortem by means of immunohistochemistry, verifying the presence of the -amyloid plaques in the patient’s brain section using specific anti -amyloid antibodies.
However, a clinical diagnosis for AD is based on:
Neuropsycologic evaluation: behavioral and cognitive tests (MMSE, CDR). Diagnosis of a possible or probable AD (“Dementia of AD type”).
Imaging techniques:MRI to detect changes in the volume of the brainPET analysis to identify areas of the brain with reduced glucose utilization
Progress has been done in the direction of using dyes/compounds that specifically recognize the -amyloid structure in both MRI and PET analysis. This would improve the quality of the diagnosis, identifying the structures (-amyloid plaques) that are specific for AD.
![Page 32: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/32.jpg)
Normal Alzheimer’s diseases
MRI
Computer graphic
MRI in Alzheimer’s disease (AD)
![Page 33: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/33.jpg)
Cortical thickness decreases with age
![Page 34: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/34.jpg)
Number of cortical neurons does not decrease with age
![Page 35: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/35.jpg)
Cerebral volume loss is associated with aging, but not necessarily with neuronal death and/or with AD.Need for diagnostic tools more specific than MRI.
![Page 36: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/36.jpg)
Characteristics of a biomarker for diagnostic purposes
-It should be already changed in the initial steps of the disease: implications for an early diagnosis of the disease, with deep impact in the success of the treatment.
-The method to access the biomarker must not be invasive
-The molecule used as a biomarker must be specific for that disease, and not be involved in other diseases. The mechanisms behind the specific changes in the disease must be clear.
-The method of analysis must be reproducible :-) and must not be expensive
-Ideally, the levels of the biomarker, once identified, should follow the progression of the disease (linear progression).
![Page 37: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/37.jpg)
Possible biomarkers in AD
-Levels of -amyloid peptides in the CSF of patients. Concerns regarding:
•The method used to take the sample of CSF (spinal injection, which is invasive).
•In the CSF of AD patients, the levels of the different species of -amyloid peptides, in particular the most aggressive A42, do not always follow the progression of the disease. In fact, levels of A42 raise in the early stages of the diseases, but drop in the late, advanced stages of the disease, maybe indicating increased deposition of secreted A42 into plaques in the brain.
•It is very difficult to correlate the amount of biomarker (in particular A42) to the amount of deposited plaques in the different stages of the disease.
•Cerebrospinal levels of hyperphoshorylated tau. However, since tau is involved also in other neurodegenerative phenomena called taupaties, it is questionable how it could be considered as a biomarker specific for AD.
![Page 38: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/38.jpg)
![Page 39: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/39.jpg)
Beta-Amyloid peptides can be detected in the ISF
![Page 40: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/40.jpg)
Amyloid plaques develop in J20APPTg mice without changes in the precursor APP
![Page 41: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/41.jpg)
Levels of soluble ISF Abeta decrease with disease progressing…
![Page 42: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/42.jpg)
…whereas levels of insoluble Abeta increase
![Page 43: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/43.jpg)
Higher levels of exogenous, NOT newly synthesized Abeta are sequestered from the ISF in plaque-rich animals
![Page 44: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/44.jpg)
Demonstration that the plaque attracts soluble Abeta
Explanation why levels of Abeta 42 in the CSF DO NOT follow the progression of the disease
![Page 45: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/45.jpg)
The Pittsburgh Compound B PIB is specifically up-taken in AD brains
![Page 46: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/46.jpg)
PIB is differentially retained in brain areas more susceptible to AD
![Page 47: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/47.jpg)
Control
Control
AD
AD
Topography of PIB retention in AD brain
![Page 48: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/48.jpg)
In AD brains, PIB uptake correlates with the progression of the disease
![Page 49: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/49.jpg)
?Are plaques a CAUSE or a CONSEQUENCE of neurite dysfunction?
![Page 50: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/50.jpg)
![Page 51: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/51.jpg)
Appearance of a novel plaque is a fast process that takes 1 week
Meyer-Luehamnn et al., Nature, 2008, 451:720
![Page 52: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/52.jpg)
Meyer-Luehamnn et al., Nature, 2008, 451:720
Formation of a plaque can occur within 24 hours
![Page 53: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/53.jpg)
Meyer-Luehamnn et al., Nature, 2008, 451:720
Plaque formation induces neurites curvature
![Page 54: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/54.jpg)
Does the cell try to get rid of it?
The plaque can be potentially toxic
![Page 55: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/55.jpg)
Meyer-Luehamnn et al., Nature, 2008, 451:720
Plaques recruit activated microglia: a possible role of microglia limiting the size of the plaque
![Page 56: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/56.jpg)
The many ways the system tries to get rid of the Abeta peptides
![Page 57: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/57.jpg)
Insulin Degrading Enzyme (IDE) is crucial for Abeta degradation
![Page 58: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/58.jpg)
IDE levels are reduced in brain areas affected by AD
![Page 59: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/59.jpg)
Decreased A plaque burden in animals overexpressing Insulin Degrading Enzyme (IDE) and Neprilysin
Leissring et al.,
![Page 60: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/60.jpg)
Is there anything we can do to help the system get rid of the plaques?
Y E S ! H E A L T H Y L I F E S T Y L E !!
![Page 61: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/61.jpg)
Abeta plaques are reduced in APPTg mice in enriched environment
![Page 62: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/62.jpg)
Abeta plaques are reduced in APPTg mice in enriched environment
![Page 63: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/63.jpg)
Environmental enrichment reduces the amyloid load
![Page 64: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/64.jpg)
Activity of IDE and neprilysin are increased with environmental enrichment:Abeta clearance is favored
![Page 65: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/65.jpg)
Exercise reduces the levels of markers of AD in CFS:Reduced levels of Abeta42…
![Page 66: Alzheimer’s disease](https://reader030.vdocument.in/reader030/viewer/2022012908/5681572f550346895dc4cc14/html5/thumbnails/66.jpg)
…and tau, phosphorylated tau